Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study.

Tristan FerryAnne ConradEric SennevilleSandrine RouxCéline Dupieux-ChabertAurélien DinhSébastien LustigSylvain GoutelleThomas BriotTruong-Thanh PhamFlorent Valour

Published in: Open forum infectious diseases (2021)

A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event.

Keyphrases

gram negative
multidrug resistant
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
emergency department
bone mineral density
patient reported outcomes
postmenopausal women
klebsiella pneumoniae
electronic health record
bone loss
replacement therapy